Table 1. Details of patients included in the study.

No.	Gender	Age (years)	Diagnosis	EDSS	Disease duration	DMT-therapy	Acute disease exacerbation/start before MRI	Symptoms of acute disease exacerbation	Symptomtic EL
1	female	30	RRMS/TL	2	17 months	none	yes/4–5 days	hemihypaesthesia left	yes
2	female	64	CIS/TL	3	new onset	none	yes/7–8 days	dysarthria/ataxia	yes
3	female	54	RRMS	2	24 years	none	yes/5–6 days	paresis right leg	yes
4	female	33	RRMS	2	new onset	none	yes/2 days	sensorimotor hemisyndrom left	yes
5	female	30	RRMS/TL	3	new onset	none	yes/3 days	hemiparesis right	yes
6	male	29	RRMS	1.5	new onset	none	yes/12 hours	retrobulbar neuritis left	no
7	female	24	RRMS	2	3 months	Betaseron®/Betaferon®	no	N/A	no
8	female	37	RRMS	6.0	6 years	none	yes/9 hours	hemiparesis left, anarthria	yes
9	female	20	RRMS	1.5	27 months	Betaseron®/Betaferon®	no	N/A	no
10	female	24	RRMS	4	26 months	Copaxone®	no	N/A	no
11	female	60	SPMS	7.5	23 years	None	yes/2 days	hemiparesis left	yes
12	female	50	RRMS	3.5	23 months	Betaseron®/Betaferon®	no	N/A	no
13	female	23	RRMS	1	new onset	none	yes/2–3 months	progressive hypesthesia in all extremities	no
14	female	44	RRMS	3.5	2 months	none	yes/3 days	dysaesthesia, ataxia, bladder disorder, fatigue	yes
15	female	35	RRMS	5.0	13 years	none	yes/4 month	progressive paresis in lower extremity	no
16	female	42	RRMS	2	new onset	none	no	spasticity in all extremities	no
17	male	74	SPMS	7	30 years	none	yes/2 days	paraparesis	no
18	male	28	RRMS	1.5	7 months	Betaseron®/Betaferon®	no	N/A	no

MS  =  Multiple Sclerosis; RRMS  =  relapsing-remitting MS; SPMS  =  secondary-progressive MS, CIS  =  clinically isolated syndrome; TL  =  tumefactive lesion; EL  =  enhancing lesion; DMT  =  disease modifying treatment; N/A  =  not applicable.